OP 2.3 – 00117 The EZH2 inhibitor Tazemetostat increases MHC I antigen presentation in vitro and in vivo, enhancing antiviral activities of HIV-specific CTLs

• A. Gramatica,
• A. Danesh,
• I. Miller,
• J. Weiler,
• F. Khan,
• D. Copertino,
• U. Chukwukere,
• L. Leyre,
• B. Jones

Affiliations

A. Gramatica

Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, USA

A. Danesh

Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, USA

I. Miller

Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, USA

J. Weiler

Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, USA

F. Khan

Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, USA

D. Copertino

Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, USA

U. Chukwukere

Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, USA

L. Leyre

Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, USA; Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, USA

B. Jones

Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, USA; Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, USA